US and Europe biosimilars, clinical trials in EU & US

Biosimilars: US and Europe

COVID-19 and its economic impacts have only strengthened the case for further developing a sustainable global biosimilars market. In this Insights@CromosPharma paper we explore the development of the European biosimilar market and contrast this with the US. We also look at the key challenges and opportunities facing biosimilar developers.

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us

OUR PUBLICATIONS